Sohrabi, Yahya
Reinecke, Holger
Soehnlein, Oliver
Article History
Received: 7 June 2022
Revised: 26 June 2022
Accepted: 10 July 2022
First Online: 23 July 2022
Competing interests
: O.S. is the advisor for ResoTher and Novo Nordisk and receives funding from Novo Nordisk to study chronopharmacological and histone-neutralizing strategies in atherosclerosis.